Compare UBFO & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBFO | LUCD |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 190.8M |
| IPO Year | 2001 | 2021 |
| Metric | UBFO | LUCD |
|---|---|---|
| Price | $10.46 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 48.2K | ★ 639.7K |
| Earning Date | 04-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.70 | N/A |
| Revenue | $2,954,000.00 | ★ $4,346,000.00 |
| Revenue This Year | N/A | $126.14 |
| Revenue Next Year | N/A | $138.77 |
| P/E Ratio | $15.01 | ★ N/A |
| Revenue Growth | 1.23 | ★ 79.00 |
| 52 Week Low | $7.80 | $0.95 |
| 52 Week High | $11.52 | $1.70 |
| Indicator | UBFO | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 50.44 |
| Support Level | $9.31 | $1.01 |
| Resistance Level | $10.53 | $1.52 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 75.00 | 45.15 |
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.